Filed Pursuant to Rule 424(b)(3)
Registration No. 333-282218
 
PROSPECTUS SUPPLEMENT NO. 4
(to Prospectus dated September 27, 2024)
 
3,384,616 Ordinary Shares
 
This Prospectus Supplement No. 4 updates, amends, and supplements the prospectus dated September 27, 2024 (as amended and supplemented, the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333- 282218). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
 
This prospectus supplement is being filed to update, amend, and supplement the information in the Prospectus with the GAAP financial statements as of, and for the three and twelve month periods ended on, December 31, 2024 (the “Q4 2024 financial statements”) included in the press release attached as Exhibit 99.1 to our Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on March 6, 2025 Accordingly, we have included the Q4 2024 financial statements in this prospectus supplement.
 
This prospectus supplement is also being filed to update, amend, and supplement the information in the Prospectus, with respect to the change in the composition of our board of directors, included in our Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on March 6, 2025.
 
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
 
As of the date of this Prospectus, our ordinary shares are listed and trade on the Nasdaq Capital Market under the symbol “EVGN”. The last reported sale price of our ordinary shares on March 5, 2025, was $1.41 per share.
 
Investing in our ordinary shares is highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 8 of the Prospectus for a discussion of information that should be considered in connection with an investment in our ordinary shares, as well as the risks described under the heading “Item 3 Key Information – D. Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, which we filed with the Securities and Exchange Commission on March 28, 2024, and in other documents incorporated by reference into the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.
 
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities, or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
 
The date of this prospectus supplement is March 6, 2025
 

 
 
UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2025
 
 Commission File Number 001-36187
 
EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
  (Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
 
CONTENTS
 
On March 6, 2025, Evogene Ltd. (“Evogene”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2024.  A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.
 
Evogene is holding a conference call on March 6, 2025 to discuss its quarterly results for the quarter ended December 31, 2024 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File Nos. 333-253300 and 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443 and 333-203856) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: March 6, 2025
  
EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
——————————————
Yaron Eldad
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.
DESCRIPTION



 
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands

   
December 31,
    
December 31,
  
   
2024
    
2023
  
CURRENT ASSETS:
            
Cash and cash equivalents
  
$
15,301
    
$
20,772
  
Short-term bank deposits
    
10
      
10,291
  
Trade receivables
    
1,091
      
357
  
Other receivables and prepaid expenses
    
2,064
      
2,973
  
Deferred expenses related to issuance of warrants
    
3,039
      
-
  
Inventories
    
1,819
      
76
  
     
23,324
      
34,469
  
LONG-TERM ASSETS:
                
Long-term deposits and other receivables
    
12
      
28
  
Investment accounted for using the equity method
    
82
      
-
  
Right-of-use-assets
    
2,447
      
980
  
    Property, plant and equipment, net
    
1,804
      
2,455
  
Intangible assets, net
    
12,195
      
13,169
  
     
16,540
      
16,632
  
                 
   
$
39,864
    
$
51,101
  
CURRENT LIABILITIES:
                
Trade payables
  
$
1,228
    
$
1,785
  
Employees and payroll accruals
    
1,869
      
2,537
  
Lease liability
    
589
      
853
  
Liabilities in respect of government grants
    
323
      
388
  
Deferred revenues and other advances
    
360
      
362
  
Warrants and pre-funded warrants liability
    
2,876
      
-
  
Convertible SAFE
    
10,371
      
-
  
Other payables
    
1,079
      
1,019
  
     
18,695
      
6,944
  
LONG-TERM LIABILITIES:
                
Lease liability
    
1,914
      
285
  
Liabilities in respect of government grants
    
4,327
      
4,426
  
Deferred revenues and other advances
    
90
      
393
  
Convertible SAFE
    
-
      
10,368
  
     
6,331
      
15,472
  
SHAREHOLDERS' EQUITY:
                
Ordinary shares of NIS 0.2 par value:
Authorized – 15,000,000 ordinary shares; Issued and outstanding – 6,795,589  shares on December 31, 2024 and 5,079,313 (*)   shares on December 31, 2023
    
363
      
286
  
Share premium and other capital reserve
    
272,257
      
269,353
  
Accumulated deficit
    
(274,071
)
    
(257,586
)
                 
 Equity attributable to equity holders of the Company
    
(1,451
)
    
12,053
  
                 
Non-controlling interests
    
16,289
      
16,632
  
                 
   Total equity
    
14,838
      
28,685
  
                 
   
$
39,864
    
$
51,101
  

(*) Shares and per shares amounts have been retroactively adjusted to reflect the reserve stock split

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS
U.S. dollars in thousands (except share and per share amounts)

   
Year ended
December 31,
    
Three months ended
December 31,
  
   
2024
    
2023
    
2024
    
2023
  
Revenues
  
$
8,511
    
$
5,640
    
$
1,611
    
$
578
  
Cost of revenues
    
2,683
      
1,692
      
755
      
398
  
                                 
Gross profit
    
5,828
      
3,948
      
856
      
180
  
                                 
Operating expenses (income):
                                
                                 
Research and development, net
    
16,648
      
20,777
      
3,401
      
5,545
  
Sales and marketing
    
3,425
      
3,611
      
650
      
1,033
  
General and administrative
    
7,441
      
6,068
      
1,372
      
1,230
  
Other expenses
    
524
      
-
      
-
      
-
  
                                 
Total operating expenses, net
    
28,038
      
30,456
      
5,423
      
7,808
  
                                 
Operating loss
    
(22,210
)
    
(26,508
)
    
(4,567
)
    
(7,628
)
                                 
Financing income
    
7,546
      
1,486
      
4,726
      
358
  
Financing expenses
    
(3,342
)
    
(965
)
    
(144
)
    
(71
)
                                 
Financing income (expenses), net
    
4,204
      
521
      
4,582
      
287
  
                                 
Share of loss of an associate
    
39
      
-
      
13
      
-
  
                                 
Gain (loss) before taxes on income
    
(18,045
)
    
(25,987
)
    
2
      
(7,341
)
Taxes on income (tax benefit)
    
9
      
(33
)
    
7
      
(4
)
                                 
Loss
  
$
(18,054
)
  
$
(25,954
)
  
$
(5
)
  
$
(7,337
)
                                 
Attributable to:
                                
Equity holders of the Company
    
(16,485
)
    
(23,879
)
    
427
      
(6,601
)
Non-controlling interests
    
(1,569
)
    
(2,075
)
    
(432
)
    
(736
)
                                 
   
$
(18,054
)
  
$
(25,954
)
  
$
(5
)
  
$
(7,337
)
                                 
Basic and diluted loss per share, attributable to equity holders of the Company (*)
  
$
(2.89
)
  
$
(5.20
)
  
$
0.06
    
$
(1.30
)
                                 
Weighted average number of shares used in computing basic and diluted loss per share (*)
    
5,697,245
      
4,589,386
      
6,795,589
      
5,079,313
  

(*) Shares and per shares amounts have been retroactively adjusted to reflect the reserve stock split.


CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands

   
 
Year ended
December 31,
    
Three months ended
December 31,
  
   
2024
    
2023
    
2024
    
2023
  
Cash flows from operating activities:
                        
                         
Loss
  
$
(18,054
)
  
$
(25,954
)
  
$
(5
)
  
$
(7,337
)
                                 
Adjustments to reconcile loss to net cash used in operating activities:
                                
                                 
    Adjustments to the profit or loss items:
                                
                                 
Depreciation and amortization
    
1,530
      
1,641
      
348
      
418
  
Amortization of intangible assets
    
974
      
971
      
245
      
245
  
Share-based compensation
    
1,795
      
1,877
      
317
      
113
  
Revaluation of convertible SAFE
    
3
      
254
      
51
      
77
  
Net financing income
    
(689
)
    
(666
)
    
(986
)
    
(460
)
Loss (gain) from sale of property, plant and equipment
    
524
      
(26
)
    
-
      
-
  
Excess of initial fair value of pre-funded warrants over transaction proceeds
    
2,684
      
-
      
-
      
-
  
Amortization of deferred expenses related to issuance of warrants
    
471
      
-
      
334
      
-
  
Remeasurement of pre-funded warrants and warrants
    
(6,529
)
    
-
      
(4,589
)
    
-
  
Associated Company loss share
    
39
      
-
      
13
      
-
  
Taxes on income (tax benefit)
    
9
      
(33
)
    
7
      
(4
)
                                 
     
811
      
4,018
      
(4,260
)
    
389
  
Changes in asset and liability items:
                                
                                 
Decrease (increase) in trade receivables
    
(734
)
    
(9
)
    
499
      
988
  
Decrease (increase) in other receivables
    
925
      
(1,445
)
    
324
      
(1,025
)
Decrease (increase) in inventories
    
(1,743
)
    
490
      
(363
)
    
37
  
Decrease in deferred taxes
    
-
      
94
      
-
      
94
  
Increase (decrease) in trade payables
    
(596
)
    
742
      
(62
)
    
563
  
Increase (decrease) in employees and payroll accruals
    
(668
)
    
550
      
(420
)
    
478
  
Increase (decrease) in other payables
    
62
      
(534
)
    
(77
)
    
(67
)
Decrease in deferred revenues and other advances
    
(559
)
    
(288
)
    
(463
)
    
(478
)
                                 
     
(3,313
)
    
(400
)
    
(562
)
    
590
  
                                 
Cash received (paid) during the period for:
                                
                                 
Interest received
    
934
      
905
      
288
      
472
  
Interest paid
    
(67
)
    
(115
)
    
(11
)
    
(23
)
Taxes paid
    
(11
)
    
(31
)
    
(11
)
    
(16
)
                                 
Net cash used in operating activities
  
$
(19,700
)
  
$
(21,577
)
  
$
(4,561
)
  
$
(5,925
)


CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands

   
 
Year ended
December 31,
    
Three months ended
December 31,
  
   
2024
    
2023
    
2024
    
2023
  
Cash flows from investing activities:
                        
                         
Purchase of property, plant and equipment
  
$
(626
)
  
$
(785
)
  
$
(322
)
  
$
(86
)
Proceeds from sale of marketable securities
    
-
      
6,924
      
-
      
-
  
Purchase of marketable securities
    
-
      
(503
)
    
-
      
-
  
Proceeds from sale of property, plant and equipment
    
58
      
26
      
-
      
-
  
Proceeds from short term bank deposits, net
    
10,190
      
(10,200
)
    
9,080
      
(500
)
                                 
Net cash provided by (used in) investing activities
    
9,622
      
(4,538
)
    
8,758
      
(586
)
                                 
Cash flows from financing activities:
                                
                                 
Issuance of a subsidiary preferred shares to non-controlling interests
    
-
      
9,523
      
-
      
-
  
Proceeds from issuance of ordinary shares, pre-funded warrants and warrants
    
5,500
      
-
      
-
      
-
  
Proceeds from issuance of ordinary shares, net of issuance expenses
    
123
      
8,449
      
-
      
45
  
Repayment of lease liability
    
(901
)
    
(836
)
    
(206
)
    
(212
)
Proceeds from government grants
    
232
      
1,089
      
-
      
20
  
Repayment of government grants
    
(298
)
    
(73
)
    
-
      
-
  
                                 
Net cash provided by (used in) financing activities
    
4,656
      
18,152
      
(206
)
    
(147
)
                                 
Exchange rate differences - cash and cash equivalent balances
    
(49
)
    
(245
)
    
(7
)
    
99
  
                                 
 Decrease in cash and cash equivalents
    
(5,471
)
    
(8,208
)
    
3,984
      
(6,559
)
                                 
Cash and cash equivalents beginning of the period
    
20,772
      
28,980
      
11,317
      
27,331
  
                                 
Cash and cash equivalents end of the period
  
$
15,301
    
$
20,772
    
$
15,301
    
$
20,772
  
                                 
Significant non-cash activities
                                
Acquisition of property, plant and equipment
  
$
120
    
$
81
    
$
120
    
$
81
  
Increase of right-of-use-asset recognized with corresponding lease liability
  
$
2,307
    
$
194
    
$
-
    
$
59
  
Exercise of pre-funded warrants
  
$
2,289
    
$
-
    
$
2,289
    
$
-
  
Investment in affiliated Company with corresponding deferred revenues
  
$
120
    
$
-
    
$
-
    
$
-
  
 
 
 

UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2025
 
 Commission File Number 001-36187
 
EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
  (Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 


 
CONTENTS
 
Evogene Ltd., or the Company, reports changes in the composition of its board of directors, or the Board. A copy of the press release announcing these changes is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”)
 
Ms. Sarit Firon has decided to step down from her role as chairperson of the Board but will continue to serve as a member of the Board. Ms. Firon will be replaced by Mr. Nir Nimrodi, who has been serving as a member of the Board since September 2022. In addition, the Company's President and CEO, Mr. Ofer Haviv, will join as a member of the Board and will remain in office until the earlier of the first annual or special general meeting of shareholders following his appointment.
 
The Company thanks Ms. Sarit Firon for her dedication and contribution to the Company as a chairperson over the years and looks forward to her continued support as a member of the Board.
 
The content of this Form 6-K (excluding Exhibit 99.1) is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
 
 
Signature
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.




Date: March 6, 2025
 
EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer


EXHIBIT INDEX
 
EXHIBIT NO.
DESCRIPTION


 


 
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Evogene Charts.
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Evogene Charts.